Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases

The Tohoku Journal of Experimental Medicine
Minami YamadaTakeshi Sasaki

Abstract

We described here four patients diagnosed with Philadelphia chromosome positive (Ph+) leukemia, consisting of chronic myeloid leukemia (CML) (n=2) and Ph+ acute lymphoblastic leukemia (ALL) (n=2). All patients were treated with imatinib mesylate (300-400 mg/day) for the treatment of relapsed CML after allogeneic hematopoietic stem cell transplantation (SCT) (n=2), relapsed Ph+ ALL after SCT (n=1), and Ph+ ALL preceding SCT (n=1). Significant clinical and molecular responses were observed in all patients and three of them achieved sustained molecular remission. Imatinib was well tolerated and did not induce noticeable graft versus host disease although one patient presented severe skin rash (Grade III). Notably, serum cyclosporine A concentration increased after the initiation of imatinib treatment, probably through competitive inhibition of P450 3A4 isoenzyme. Our data suggest that imatinib in conjunction with SCT for the Ph+ leukemia may be a promising treatment strategy.

References

Sep 13, 2003·Leukemia·E OlavarriaUNKNOWN Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT)

❮ Previous
Next ❯

Citations

Nov 26, 2011·Investigational New Drugs·Karen E MulderMichael B Sawyer
Dec 6, 2006·The Tohoku Journal of Experimental Medicine·Izumi IshikawaTakeshi Sasaki
Nov 23, 2006·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M D LeeL Gong
Mar 12, 2016·European Journal of Clinical Pharmacology·Ferdows AtiqJorie Versmissen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.